CHILDRENS HOSPITAL
- Type
- Teaching hospital
- Where
- Washington, DC
- Medicare CCN
- 093300
- Received
- $1,830,804 in 393 records, 2023 ($746,488 general, $1,084,315 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2023 | General payment | 81 | $746,488 |
| 2023 | Research payment | 312 | $1,084,315 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 312 | $1,084,315 |
| Grant | 1 | $650,000 |
| Consulting Fee | 37 | $36,200 |
| Long term medical supply or device loan | 21 | $29,290 |
| Charitable Contribution | 1 | $15,000 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 4 | $9,135 |
| Space rental or facility fees (teaching hospital only) | 4 | $4,250 |
| Debt forgiveness | 12 | $2,562 |
| Education | 1 | $51 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | Siemens Medical Solutions USA, Inc. | $31,709 | Research payment | In-kind items and services | Artis zee multi-purpose Device, AT - Fixed interventional x-ray/angiography fluoroscopy | CNMC Kanter AX Interventional Cardiology | 2023 |
| 2023-12-31 | Linvatec Corporation | $684 | Long term medical supply or device loan | In-kind items and services | HALL POWER Device, ORTHOPEDIC SURGERY | 2023 | |
| 2023-12-31 | Stryker Corporation | $390 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-12-31 | Siemens Medical Solutions USA, Inc. | $387 | Debt forgiveness | In-kind items and services | 2023 | ||
| 2023-12-31 | Novartis Pharmaceuticals Corporation | $8 | Research payment | In-kind items and services | A Randomized, Sham-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Intrathecal OAV101 in Patients | 2023 | |
| 2023-12-29 | Zimmer Biomet Holdings, Inc. | $630 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-12-29 | Zimmer Biomet Holdings, Inc. | $439 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-12-18 | Fisher Scientific Company L.L.C. | $720 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-12-18 | Fisher Scientific Company L.L.C. | $523 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-12-18 | Fisher Scientific Company L.L.C. | $374 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-12-18 | Fisher Scientific Company L.L.C. | $328 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-12-18 | Fisher Scientific Company L.L.C. | $274 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-12-18 | Fisher Scientific Company L.L.C. | $183 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-12-14 | GE HEALTHCARE | $100 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-12-12 | PFIZER INC. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2023 | ||
| 2023-12-08 | JAZZ PHARMACEUTICALS INC. | $23 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A PHASE 1/2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS (PK), RECOMMENDED PHASE 2 DOSE (RP2 | 2023 |
| 2023-12-08 | JAZZ PHARMACEUTICALS INC. | $23 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A PHASE 1/2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS (PK), RECOMMENDED PHASE 2 DOSE (RP2 | 2023 |
| 2023-12-08 | JAZZ PHARMACEUTICALS INC. | $23 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A PHASE 1/2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS (PK), RECOMMENDED PHASE 2 DOSE (RP2 | 2023 |
| 2023-12-08 | JAZZ PHARMACEUTICALS INC. | $23 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A PHASE 1/2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS (PK), RECOMMENDED PHASE 2 DOSE (RP2 | 2023 |
| 2023-12-08 | JAZZ PHARMACEUTICALS INC. | $23 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A PHASE 1/2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS (PK), RECOMMENDED PHASE 2 DOSE (RP2 | 2023 |
| 2023-12-08 | JAZZ PHARMACEUTICALS INC. | $15 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A PHASE 1/2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS (PK), RECOMMENDED PHASE 2 DOSE (RP2 | 2023 |
| 2023-12-08 | JAZZ PHARMACEUTICALS INC. | $15 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A PHASE 1/2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS (PK), RECOMMENDED PHASE 2 DOSE (RP2 | 2023 |
| 2023-12-08 | JAZZ PHARMACEUTICALS INC. | $15 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A PHASE 1/2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS (PK), RECOMMENDED PHASE 2 DOSE (RP2 | 2023 |
| 2023-12-08 | JAZZ PHARMACEUTICALS INC. | $15 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A PHASE 1/2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS (PK), RECOMMENDED PHASE 2 DOSE (RP2 | 2023 |
| 2023-12-08 | JAZZ PHARMACEUTICALS INC. | $15 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A PHASE 1/2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS (PK), RECOMMENDED PHASE 2 DOSE (RP2 | 2023 |
| 2023-12-08 | JAZZ PHARMACEUTICALS INC. | $15 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A PHASE 1/2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS (PK), RECOMMENDED PHASE 2 DOSE (RP2 | 2023 |
| 2023-12-08 | JAZZ PHARMACEUTICALS INC. | $15 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A PHASE 1/2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS (PK), RECOMMENDED PHASE 2 DOSE (RP2 | 2023 |
| 2023-12-08 | JAZZ PHARMACEUTICALS INC. | $15 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A PHASE 1/2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS (PK), RECOMMENDED PHASE 2 DOSE (RP2 | 2023 |
| 2023-12-08 | JAZZ PHARMACEUTICALS INC. | $15 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A PHASE 1/2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS (PK), RECOMMENDED PHASE 2 DOSE (RP2 | 2023 |
| 2023-12-08 | JAZZ PHARMACEUTICALS INC. | $15 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A PHASE 1/2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS (PK), RECOMMENDED PHASE 2 DOSE (RP2 | 2023 |
| 2023-12-08 | JAZZ PHARMACEUTICALS INC. | $4 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A PHASE 1/2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS (PK), RECOMMENDED PHASE 2 DOSE (RP2 | 2023 |
| 2023-12-08 | JAZZ PHARMACEUTICALS INC. | $2 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | A PHASE 1/2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS (PK), RECOMMENDED PHASE 2 DOSE (RP2 | 2023 |
| 2023-11-28 | SANOFI PASTEUR INC. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2023 | ||
| 2023-11-22 | Novo Nordisk AS | $1,873 | Research payment | Cash or cash equivalent | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-14 | Novartis Pharmaceuticals Corporation | $9,375 | Research payment | Cash or cash equivalent | A One Month, Investigator and Participant Blinded Study to Investigate the Efficacy and Safety of Remibrutinib (LOU064) | 2023 | |
| 2023-10-25 | Novo Nordisk AS | $1,125 | Research payment | Cash or cash equivalent | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-10-20 | National Marrow Donor Program | $720 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-10-18 | Takeda Pharmaceuticals U.S.A., Inc. | $16,250 | Research payment | Cash or cash equivalent | PHASE 3, MULTICENTER, RANDOMIZED STUDY WITH 2 DIFFERENT DOSES OF PRUCALOPRIDE ADMINISTERED TO MALE AND FEMALE PEDIATRIC | 2023 | |
| 2023-09-30 | Olympus America Inc. | $24 | Debt forgiveness | In-kind items and services | SINGLE USE SUCTION VALVE (Sterile) Device, Endotherapy | 2023 | |
| 2023-09-22 | Novo Nordisk AS | $1,575 | Research payment | Cash or cash equivalent | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-09-18 | Novartis Pharmaceuticals Corporation | $86,782 | Research payment | In-kind items and services | TAFINLAR Drug, Oncology | An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabr | 2023 |
| 2023-09-18 | Fisher Scientific Company L.L.C. | $1,150 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-09-18 | Fisher Scientific Company L.L.C. | $973 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-09-18 | Fisher Scientific Company L.L.C. | $583 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-09-18 | Fisher Scientific Company L.L.C. | $197 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-09-18 | Fisher Scientific Company L.L.C. | $100 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-09-18 | Fisher Scientific Company L.L.C. | $96 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-09-15 | Novartis Pharmaceuticals Corporation | $22 | Research payment | In-kind items and services | KYMRIAH Drug, Oncology | A single arm phase II trial in first line high risk HR pediatric and young adult patients with Bcell acute lymphoblastic | 2023 |
| 2023-09-11 | Baxter Healthcare | $36 | Long term medical supply or device loan | In-kind items and services | Hillrom - CP 150 Resting Electrocardiograph Device, Cardiology/Vascular Diseases | 2023 | |
| 2023-09-07 | Bio-Rad Laboratories, Inc. | $26 | Debt forgiveness | Cash or cash equivalent | IH-1000 Device, Immunohematology | 2023 | |
| 2023-09-05 | Becton, Dickinson and Company | $51 | Education | In-kind items and services | 2023 | ||
| 2023-08-28 | Novartis Pharmaceuticals Corporation | $1,486 | Research payment | In-kind items and services | KYMRIAH Drug, Oncology | A single arm phase II trial in first line high risk HR pediatric and young adult patients with Bcell acute lymphoblastic | 2023 |
| 2023-08-24 | E.R. Squibb & Sons, L.L.C. | $1,000 | Research payment | Cash or cash equivalent | SPRYCEL Drug, Oncology | Phase II Pediatric Ph+ ALL - A Phase 2 Multi-Center, Historically-Controlled Study of Dasatinib Added to Standard Chemot | 2023 |
| 2023-08-18 | Novo Nordisk AS | $3,489 | Research payment | Cash or cash equivalent | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novartis Pharmaceuticals Corporation | $19,233 | Research payment | In-kind items and services | XOLAIR Drug, Pulmonary/Respiratory Diseases | Omalizumab Before Onset of Exacerbations URI-induc. asthma exacerbation | 2023 |
| 2023-08-17 | E.R. Squibb & Sons, L.L.C. | $8,500 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | COOP/ISR ph I Adolescent Melanoma | 2023 |
| 2023-08-17 | Novo Nordisk AS | $25 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $25 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $25 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $25 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
The latest 200 records of 393.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Washington, DC, county District of Columbia, DC, state District of Columbia; placed by its city name.
| Measure | Place (city or town) Washington, DC | County District of Columbia, DC | State District of Columbia |
|---|---|---|---|
| Population B01003 | 681,294 | 681,294 | 681,294 |
| Population, 2020 census P1 | 689,545 | 689,545 | 689,545 |
| Median age B01002 | 34.9 | 34.9 | 34.9 |
| Under 18 B01001 | 18.7% | 18.7% | 18.7% |
| 65 and over B01001 | 12.8% | 12.8% | 12.8% |
| Households B11001 | 324,491 | 324,491 | 324,491 |
| Foreign born B05002 | 14.3% | 14.3% | 14.3% |
| Median household income B19013 | $109,870 | $109,870 | $109,870 |
| Median family income B19113 | $155,025 | $155,025 | $155,025 |
| Per capita income B19301 | $77,348 | $77,348 | $77,348 |
| Poverty rate B17001 | 15.4% | 15.4% | 15.4% |
| Unemployment rate B23025 | 6.3% | 6.3% | 6.3% |
| Civilian labor force B23025 | 400,406 | 400,406 | 400,406 |
| Mean commute (minutes) B08013 | 30.0 | 30.0 | 30.0 |
| Bachelor's degree or higher B15003 | 64.2% | 64.2% | 64.2% |
| Housing units B25001 | 361,014 | 361,014 | 361,014 |
| Owner-occupied B25003 | 41.5% | 41.5% | 41.5% |
| Renters B25003 | 58.5% | 58.5% | 58.5% |
| Median home value B25077 | $737,100 | $737,100 | $737,100 |
| Median gross rent B25064 | $1,954 | $1,954 | $1,954 |
| White, not Hispanic B03002 | 36.5% | 36.5% | 36.5% |
| Black B03002 | 41.6% | 41.6% | 41.6% |
| Hispanic or Latino B03002 | 11.9% | 11.9% | 11.9% |
| Asian B03002 | 4.3% | 4.3% | 4.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 5.6% in Sep 2026 (6.6% a year earlier); per capita personal income $119,772 in 2025, up 32% in five years (+6.5% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Washington, DC.
Comments